Pfizer Inc (PFE DU) stock market data APIs
€21.165
-0.02(-0.1%)
as of December 29, 2025
Try our APIs with
free plan!
Pfizer Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for PFE.DU.
Prev. Close
21.165
Open
21.1438
High
21.4338
Low
21.084
52 wk Range
17.8936-24.6914
Market Cap
262 316 M
Dividends (Yield)
0.0347
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pfizer Inc data using free add-ons & libraries
Get Pfizer Inc Fundamental Data
Pfizer Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pfizer Inc News
New
Here’s What Analysts Think About Pfizer Inc. (PFE)
Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price targe...
This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year
Bristol Myers Squibb could become the pharmaceutical industry’s turnaround story for 2026. Shares are off 9% in 2025 after a series of drug pipeline disappointments, while major patent expirations, ...
This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%
Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth. Continue Reading
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
CorMedix CRMD took a major step to diversify its revenue base and lessen reliance on its lead marketed product, DefenCath (Taurolidine + Heparin), by acquiring Melinta Therapeutics for $300 million in...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
